• Mayzent is a drug that is taken orally once a day and acts with the mechanism of an S1P receptor modulator – preventing the release of immune T cells from lymph nodes into the blood. Mayzent helps prevent penetration of T cells from the blood into the brain and spinal cord and has proven high efficacy in delaying disease progression.
• In a phase 3 study, Mayzent was able to slow the effects of disease activity, such as a decrease in seizures and brain lesions, as well as a slowdown in worsening disability. Mayzent was also able to show a reduction in the risk of cognitive decline and delayed wheelchair dependency (EDSS≥7) by an average of 7.9 years.
• Mayzent is broken down by CYP2C9, and therefore, patients should have a simple genetic test to characterize the genotype of this enzyme to adjust the correct dose for them.
• The clearance time of Mayzent from the body is relatively short compared to other drugs in multiple sclerosis – only 6 days.
• COVID 19 – From studies and evidence accumulated during the COVID-19 period, it was found that the immune response to the COVID-19 vaccine was higher among Mayzent patients (66%) compared to patients treated with fingolimod from the same class of drugs.
• Do not get pregnant under Mayzent treatment and up to 10 days after stopping treatment.
• Common side effects: Macular edema – reversible condition if diagnosed early, infections, increased liver function, increased blood pressure, shingles.

Availability: The treatment is available in the medication basket for RRMS patients and in the SBS basket in Clalit and in Maccabi for active SPMS patients as well.

Image: christina-victoria-craft-unsplash